Suven Life Sciences Limited (BOM:530239)
India · Delayed Price · Currency is INR 372.40
-2.05 (-0.55%)
At close: Aug 21, 2026
Suven Life Sciences Cash Flow Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Operating Activities
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Net Income | -2,763 | -1,607 | -1,051 | -1,183 | -1,220 |
Depreciation & Amortization | 55.17 | 57.92 | 64.75 | 65.17 | 43.7 |
Other Amortization | 0.96 | 0.3 | 0.27 | 0.26 | 0.23 |
Loss (Gain) From Sale of Investments | -95.37 | -49.76 | -45.49 | -17.92 | -3.56 |
Stock-Based Compensation | 17.87 | 12.75 | - | - | - |
Other Operating Activities | -46.07 | -55.45 | -192.35 | -139.46 | -56.52 |
Change in Accounts Receivable | -1.72 | -0.51 | -4.79 | 4.91 | 4.64 |
Change in Inventory | 1.36 | 4.71 | -7.08 | 0.22 | 1.19 |
Change in Accounts Payable | -6.56 | 31.59 | 4.03 | -3.22 | -10.09 |
Change in Other Net Operating Assets | -176.35 | 64.86 | 76.73 | 112.9 | -35.02 |
Operating Cash Flow | -3,014 | -1,541 | -1,155 | -1,160 | -1,275 |
Operating Cash Flow Growth | - | - | - | - | - |
Investing Activities
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Capital Expenditures | -50.83 | -372.76 | - | -28.95 | -197.72 |
Sale of Property, Plant & Equipment | - | - | 24.21 | - | - |
Investment in Securities | -1,538 | 607.24 | 775.18 | -1,042 | -447.21 |
Other Investing Activities | -3,032 | 1,315 | 144.97 | -1,408 | 8.14 |
Investing Cash Flow | -4,621 | 1,550 | 944.36 | -2,478 | -222.29 |
Financing Activities
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Long-Term Debt Repaid | -3.73 | -7.1 | -8.96 | -16.03 | -15.55 |
Total Debt Repaid | -3.73 | -7.1 | -8.96 | -16.03 | -15.55 |
Net Debt Issued (Repaid) | -3.73 | -7.1 | -8.96 | -16.03 | -15.55 |
Issuance of Common Stock | 11.77 | - | - | 3,974 | 1,476 |
Other Financing Activities | 7,560 | -0.47 | -1.58 | -2.62 | -3.95 |
Financing Cash Flow | 7,568 | -7.56 | -10.54 | 3,955 | 1,457 |
Net Cash Flow
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Miscellaneous Cash Flow Adjustments | 0 | - | 0 | - | - |
Net Cash Flow | -67.46 | 0.93 | -220.87 | 317.46 | -40.75 |
Free Cash Flow
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Free Cash Flow | -3,065 | -1,914 | -1,155 | -1,189 | -1,473 |
Free Cash Flow Growth | - | - | - | - | - |
Free Cash Flow Margin | -4307.95% | -2875.39% | -987.51% | -874.42% | -1232.64% |
Free Cash Flow Per Share | -13.46 | -8.78 | -5.29 | -6.67 | -10.93 |
Levered Free Cash Flow | -2,013 | -1,252 | -684.75 | -826.32 | -616.13 |
Unlevered Free Cash Flow | -2,012 | -1,252 | -683.76 | -824.52 | -612.81 |
Additional Metrics
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Cash Interest Paid | - | 0.47 | 1.58 | 2.62 | 3.95 |
Cash Income Tax Paid | 7.59 | -6.05 | -61.77 | 11.02 | 5.2 |
Change in Working Capital | -183.27 | 100.65 | 68.89 | 114.81 | -39.27 |